Search the evidence

Find the signal.

Search titles, impact clusters, countries, organizations and the full text of every analysis.

3 stories found

An ordinary chest CT reveals a small illuminated esophageal lesion while an AI triage path directs the patient toward confirmatory endoscopy.
Social good & healthChina and international validation sites+4 clusters01

AI found hidden esophageal cancers in CT scans patients already had

A multicenter Nature Medicine study reports that an AI system called EAGLE can identify esophageal cancer and precancerous lesions in noncontrast chest CT scans that were not acquired specifically for the esophagus. The model was trained on 6,813 patients and validated across 12 centers in three countries involving 80,612 patients. In external cohorts totaling 11,466 people, it reached 90.0 percent sensitivity for cancer and 98.5 percent specificity, while sensitivity for precancerous lesions was lower at 52.5 percent. A calibration cohort of 35,402 patients reduced false positives by 72.7 percent while preserving sensitivity. In a prospective hospital cohort of 17,446 patients, 38 of 90 positive predictions were true positives, producing a 42.2 percent positive predictive value and 87.8 percent sensitivity for cancer. A real-world low-dose screening cohort of 10,959 people reported 99.94 percent specificity. The opportunity is unusually practical: use scans already being performed to identify people who should receive confirmatory endoscopy. But the strongest efficiency claims remain modeled. Simulations suggested triage could triple detection, reduce diagnostic time by 70.4 percent, and lower costs in seven of eight countries. Those are not randomized outcomes or evidence of reduced mortality. Most data came from China, follow-up was under two years, endoscopy adherence was limited, and broader validation is needed for different disease patterns. EAGLE may make existing imaging more valuable. It has not yet proved that population deployment improves survival or avoids harmful overdiagnosis.

10 min
Paper-cut diagnostic panels and a clinician's hand suggest careful evaluation of imaging AI.
Social good & healthGlobal+1 clusters02

Medical AI has promising signals. Patients need proof of benefit.

These are results worth taking seriously—not because they settle the case for medical AI, but because they make the next questions sharper. A fracture-detection umbrella review covered 50 reviews and 387 primary studies. Its pooled sensitivity was 89.7% and specificity 90.4%, but certainty was generally low or very low. Comparisons between clinicians, standalone AI and assisted clinicians remained inconclusive. No included review reported adverse events or other safety outcomes. That is missing evidence, not a clean bill of health. A separate BREST-AI study examined three-year breast-cancer risk from negative screening mammograms. In external UK case–control validation, its AUC was 0.751 versus 0.700 for Mirai. The smaller US comparison did not demonstrate a statistically significant improvement. AUC measures ranking performance across thresholds; 0.751 does not mean that 75.1% of women received a correct diagnosis. The promise is real enough to investigate. Better risk stratification might help target follow-up, while better fracture detection might help clinicians notice an injury. But a useful score becomes a useful service only through decisions: who gets another examination, who waits, who receives reassurance and who is exposed to unnecessary procedures. NICE's conditional approach to certain fracture tools offers a practical model: use as an adjunct while gathering evidence, rather than substituting software for definitive review. These two new papers do not establish reduced mortality or safer care. They tell us where to look next, and which outcomes deserve to decide whether a promising tool earns a lasting place.

3 min
A precise national-policy dossier shows AI benefits passing through signed safety, worker-support, and human-control checkpoints before a scale gate opens.
Law & informationSingapore+4 clusters03

Singapore puts human control at the center of national AI adoption

Singapore’s 2026 National Day Rally framed AI adoption as a national bargain rather than an unrestricted technology race. The prime minister highlighted AI agents for small businesses, personalized exercise plans, breast-cancer screening support, genomics, and autonomous-vehicle trials. He also said adoption should not run ahead of the country’s ability to retrain and support affected workers, that autonomous vehicles should scale only after safety is proven, and that people must remain in control as capable agents create harder-to-predict risks. The speech committed Singapore to practical safeguards at home and coalitions for international rules, while stopping short of specifying every enforcement mechanism or timetable. The value of the approach is its sequence: prove the system, govern the risk, support the people disrupted, then scale. That standard now needs measurable implementation through named regulators, published stop conditions, worker outcomes, incident disclosure, and public evidence that human control is operational rather than ceremonial.

5 min